Abstract

The aim of the study was to determine the efficacy of the bismuth drugs in patients with gastric ulcer, receiving cytotoxic therapy.Peptic ulcer, in patients receiving combination chemotherapy, dyspeptic syndrome is characterized by severe, advanced stage and a relatively low degree of chronic gastritis and H. pylori contamination of the gastric mucosa. In patients receiving combination chemotherapy is determined by a significant level of violation of regeneration in the form of atrophy, intestinal metaplasia, dysplasia of the gastric mucosa associated with serious violations of cell homeostasis, under the control of regulatory molecules PCNA, Bcl-2, NF-kB and tachykinins (substance P, neurokinin A). In the subgroup of patients receiving regimens as part of peptic ulcer drugs bismuth less determined violations of the chair (p <0.05) were verified lower rates of expression of factor NF-kB (p<0.05). The rate of healing of ulcers in the subgroup of patients receiving the therapy as part of bismuth preparations did not differ significantly (р˃0.05)occasionally scarring ulcers in the subgroup of those treated without drugs bismuth.

Authors and Affiliations